The protective effect of VSL#3 on intestinal permeability in a rat model of alcoholic intestinal injury

BMC Gastroenterology

Bingyuan Wang²  Dai Zhang²  Jing Tong²  Ying wang²  Lixuan Sang¹  Bing Chang² 

[1] Department of Cadre Ward II, First Affiliated Hospital of China Medical University, 110001 Shenyang, Liaoning Province, China;Department of Gastroenterology, First Affiliated Hospital of China Medical University, 110001 Shenyang, Liaoning Province, China

关键词: Glutamine;    VSL#3;    Tight junctions;    TNFα;    Intestinal barrier;   

Others  :  857538
DOI  :  10.1186/1471-230X-13-151

 received in 2013-05-30, accepted in 2013-10-13,  发布年份 2013

【 摘 要 】

Background

This study aimed to investigate the mechanism of the probiotic VSL#3 in acute alcoholic intestinal injury, and evaluate the effect of VSL#3, glutamine,VSL#3+glutamine and heat-killed VSL#3 therapy in a rat model.

Methods

Six- to eight-week-old male wild-type rats were divided into seven groups. To establish the acute alcohol liver disease model, rats received three doses of corn starch dissolved in PBS/40% alcohol administered intra-gastrically every 12 hours. Treatment groups received an intra-gastric dose of VSL#3, Glutamine, heat-killed VSL#3, or VSL#3+Glutamine 30 minutes prior to alcohol administration. The placebo group was treated with PBS prior to alcohol administration. TNFα and endotoxin in plasma was measured by ELISA and Tachypleus Ameboctye Lysate assays, and electron microscopy, Western blotting, and reverse transcription polymerase chain reaction were used to identify the mechanisms of VSL#3 in the regulation of epithelial permeability.

Results

First, compared with control group, endotoxin and TNFα in alcohol group was obviously high. At the same time, in VSL#3 group,the expression of endotoxin and TNFα obviously lower than the alcohol group. And the trends of the expression of tight junction proteins in these groups were reversed with the change of endotoxin and TNFα. Second, compared the groups of VSL#3 with glutamine,VSL#3+glutamine and heat-killed VSL#3,we found that both VSL#3 and heat-killed VSL#3, glutamine were as effective as VSL#3+glutamine in the treatment of acute alcohol liver disease, the expression of endotoxin and TNFα were lower than the alcohol group, and tight junction proteins were higher than the alcohol group whereas the expression of tight junction proteins were higher in VSL#3 + glutamine group than either agent alone, but have no significant difference.

Conclusion

We conclude that VSL#3 treatment can regulate the ecological balance of the gut microflora, preventing passage of endotoxin and other bacterial products from the gut lumen into the portal circulation and down-regulating the expression of TNFα, which could otherwise down-regulate the expression of tight junction proteins and increase epithelial permeability.

【 授权许可】

   
2013 Chang et al.; licensee BioMed Central Ltd.

【 图 表 】

【 参考文献 】

• [1]Stewart S, Jones D, Day CP: Alcoholic liver disease: new insights into mechanisms and preventative strategies. Trends Mol Med 2001, 7(9):408-413.
• [2]Rouault TA: Hepatic iron overload in alcoholic liver disease: why does it occur and what is its role in pathogenesis? Alcohol 2003, 30(2):103-106.
• [3]Keshavarzian A, Holmes EW, Patel M, et al.: Leaky gut in alcoholic cirrhosis: a possible mechanism for alcohol-induced liver damage. Am J Gastroenterol 1999, 94(1):200-207.
• [4]Ma TY, Iwamoto GK, Hoa NT, et al.: TNF-alpha-induced increase in intestinal epithelial tight junction permeability requires NF-κB activation. Am J Physiol Gastrointest Liver Physiol 2004, 286(3):G367-G376.
• [5]Bengmark S: Ecological control of the gastroinstinal tract: the role of probiotic flore. Gut 1998, 42(1):2-7.
• [6]Simon GL, Gorbach SL: Intestinal flora in health and disease. Gastroenterology 1984, 86(1):174-193.
• [7]Guarner C, Runyon BA, Young S, et al.: Intestinal bacterial overgrowth and bacterial translocation in cirrhotic rats with ascites. J Hepatol 1997, 26(6):1372-1378.
• [8]MacFie J, O’Boyle C, Mitchell C, et al.: Gut origin of sepsis: a prospective study investigating associations between bacterial translocation, gastric microflora, and septic morbidity. Gut 1999, 45(2):223-228.
• [9]Othman M, Agfiero R, Lin HC: Alterations in intestinal microbial flora and human disease. Curr Opin Gastroenterol 2008, 24(1):11-16.
• [10]Shimizu K, Ogura H, Goto M, et al.: Altered gut flora and environment in patients with severe SIRS. J Trauma 2006, 60(1):126-133.
• [11]Li LJ, Wu ZW, Xiao DS, et al.: Changes of gut flora and endotoxin in rats with D-galactosamine induced acute liver failure. World J Gastroenterol 2004, 10(14):2087-2090.
• [12]Fuller R: Probiotics in man and animals. J Appl Bacteriol 1989, 66(5):365-378.
• [13]Abubucker S, Segata N, Goll J, et al.: Metabolic reconstruction for metagen -omic data and its application to the human microbiome. PLoS Comput Biol 2012, 8(6):e1002358.
• [14]Brown CT, Davis-Richardson AG, Giongo A, et al.: Gut microbiome meta genomics analysis suggests a functional model for the development of autoimmunity for type 1 diabetes. PLoS One 2011, 6(10):e25792.
• [15]Lakhdari O, Cultrone A, Tap J, et al.: Functional metagenomics: a high through- put screening method to decipher microbiota-driven NF-κB modulation in the human gut. PLoS One 2010, 5(9):e13092.
• [16]Murphy EF, Cotter PD, Healy S, et al.: Composition and energy harvesting capacity of the gut microbiota: relationship to diet, obesity and time in mouse models. Gut 2010, 59(12):1635-1642.
• [17]Qin J, Li R, Raes J, et al.: A human gut microbial gene catalogue established by metagenomic sequencing. Nature 2010, 464(7285):59-65.
• [18]Claesson MJ, Cusack S, O’Sullivan O, et al.: Composition, variability, and temporal stability of the intestinal microbiota of the elderly. Proc Natl Acad Sci USA 2011, 108(Suppl 1):4586-4591.
• [19]Jalanka-Tuovinen J, Salonen A, Nikkila J, et al.: Intestinal microbiota in healthy adults: temporal analysis reveals individual and common core and relation to intestinal symptoms. PLoS One 2011, 6(7):e23035.
• [20]Nam YD, Jung MJ, Roh SW, et al.: Comparative analysis of Korean human gut microbiota by barcoded pyrosequencing. PLoS One 2011, 6(7):e22109.
• [21]Reeves AE, Theriot CM, Bergin IL, et al.: The interplay between microbiome dynamics and pathogen dynamics in a murine model of Clostridium difficile Infection. Gut Microbes 2011, 2(3):145-158.
• [22]Sjogren YM, Jenmalm MC, Bottcher MF, et al.: Altered early infant gut micro- biota in children developing allergy up to 5 years of age. Clin Exp Allergy 2009, 39(4):518-526.
• [23]Deitch EA: Bacterial translocation or lymphatic drainage of toxic products from the gut: what is important in human beings? Surgery 2002, 131(3):241-244.
• [24]Rajilić-Stojanović M, Smidt H, de Vos WM: Diversity of the human gastrointestinal tract microbiota revisited. Environ Microbiol 2007, 9(9):2125-2136.
• [25]Ko TC, Beauchamp RD, Townsend CM Jr, et al.: Glutamine is essential for epidermal growth factor-stimulated intestinal cell proliferation. Surgery 1993, 114(2):147-153.
• [26]Scheppach W, Loges C, Bartram P, et al.: Effect of free glutamine and alanyl-glutamine dipeptide on mucosal proliferation of the human ileum and colon. Gastroenterology 1994, 107(2):429-434.
• [27]Buchman AL, Moukarzel AA, Bhuta S, et al.: Parenteral nutrition is associated with intestinal morphologic and functional changes in humans. JPEN J Parenter Enteral Nutr 1995, 19(6):453-460.
• [28]Van der Hulst RR, van Kreel BK, von Meyenfeldt MF, et al.: Glutamine and the preservation of gut integrity. Lancet 1993, 341(8857):1363-1365.
• [29]Musch MW, Ciancio MJ, Sarge K, et al.: Induction of heat shock protein 70 protects intestinal epithelial IEC-18 cells from oxidant and thermal injury. Am J Physiol 1996, 270(2 pt 1):C429-C436.
• [30]Wischmeyer PE, Musch MW, Madonna MB, et al.: Glutamine protects intestinal epithelial cells: role of inducible HSP70. Am J Physiol 1997, 272(2 pt 1):G879-G884.
• [31]Ameho CK, Adjei AA, Harrison EK, et al.: Prophylactic effect of dietary glutamine supplementation on interleukin 8 and tumour necrosis factor alpha production in trinitrobenzene sulphonic acid induced colitis. Gut 1997, 41(4):487-93.
• [32]Vicario M, Amat C, Rivero M, Moreto M, et al.: Dietary glutamine affects mucosal functions in rats with mild DSS-induced colitis. J Nutr 2007, 137(8):1931-1937.
• [33]Ziegler TR, Evans ME, Fernandez-Estivariz C, et al.: Trophic and cytoprotective nutrition for intestinal adaptation, mucosal repair, and barrier function. Annu Rev Nutr 2003, 23:229-61.
• [34]Lecleire S, Hassan A, Marion-Letellier R, et al.: Combined glutamine and argin- ine decrease proinflammatory cytokine production by biopsies from Crohn’s patients in association with changes in nuclear factor-kappa B and p38 mitogen-activated protein kinase pathways. J Nutr 2008, 138(12):2481-2486.
• [35]Coeffier M, Marion R, Ducrotte P, et al.: Modulating effect of glutamine on IL-1beta-induced cytokine production by human gut. Clin Nutr 2003, 22(4):407-413.
• [36]Huang Y, Li N, Liboni K, et al.: Glutamine decreases lipopolysaccharide-induced IL-8 production in Caco-2 cells through a non-NF-kappaB p50 mechanism. Cytokine 2003, 22(2–3):77-83.
• [37]Liboni KC, Li N, Scumpia PO, et al.: Glutamine modulates LPS-induced IL-8 production through IkκB/NF-κB in human fetal and adult intestinal epithelium. J Nutr 2005, 135(2):245-251.
• [38]Hubert-Buron A, Leblond J, Jacquot A, et al.: Glutamine pretreatment reduces IL-8 production in human intestinal epithelial cells by limiting IκBα ubiquitination. J Nutr 2006, 136(6):1461-1465.
• [39]Fillmann H, Kretzmann NA, San-Miguel B, et al.: Glutamine inhibits over-expression of pro-inflammatory genes and down-regulates the nuclear factor kappaB pathway in an experimental model of colitis in the rat. Toxicology 2007, 236(3):217-226.
• [40]Brasse-Lagnel C, Lavoinne A, Loeber D, et al.: Glutamine and interleukin-1beta interact at the level of Sp1 and nuclear factor-kappaB to regulate argininosuccinate synthetase gene expression. FEBS J 2007, 274(20):5250-5262.